Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension

J. Jordan; R. Stinkens; T. Jax; S. Engeli; E. E. Blaak; M. May; B. Havekes; C. Schindler; D. Albrecht; P. Pal; T. Heise; G. H. Goossens; T. H. Langenickel

doi:10.1002/cpt.455

Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension

J. Jordan^*, R. Stinkens, T. Jax, S. Engeli, E. E. Blaak, M. May, B. Havekes, C. Schindler, D. Albrecht, P. Pal, T. Heise, G. H. Goossens, T. H. Langenickel

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

58 Citations (Web of Science)

Original language	English
Pages (from-to)	254-263
Number of pages	10
Journal	Clinical Pharmacology & Therapeutics
Volume	101
Issue number	2
DOIs	https://doi.org/10.1002/cpt.455
Publication status	Published - Feb 2017

Keywords

HEART-FAILURE
LIPOLYSIS
LCZ696
METABOLISM
EFFICACY
ADIPOSE
HUMANS
SYSTEM
RISK
MEN

Access to Document

10.1002/cpt.455

Cite this

Jordan, J., Stinkens, R., Jax, T., Engeli, S., Blaak, E. E., May, M., Havekes, B., Schindler, C., Albrecht, D., Pal, P., Heise, T., Goossens, G. H., & Langenickel, T. H. (2017). Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension. Clinical Pharmacology & Therapeutics, 101(2), 254-263. https://doi.org/10.1002/cpt.455

Jordan, J. ; Stinkens, R. ; Jax, T. ; Engeli, S. ; Blaak, E. E. ; May, M. ; Havekes, B. ; Schindler, C. ; Albrecht, D. ; Pal, P. ; Heise, T. ; Goossens, G. H. ; Langenickel, T. H. / Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension. In: Clinical Pharmacology & Therapeutics. 2017 ; Vol. 101, No. 2. pp. 254-263.

@article{7315c3bc133148cf8e4767248a02a6de,

title = "Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension",

keywords = "HEART-FAILURE, LIPOLYSIS, LCZ696, METABOLISM, EFFICACY, ADIPOSE, HUMANS, SYSTEM, RISK, MEN",

author = "J. Jordan and R. Stinkens and T. Jax and S. Engeli and Blaak, {E. E.} and M. May and B. Havekes and C. Schindler and D. Albrecht and P. Pal and T. Heise and Goossens, {G. H.} and Langenickel, {T. H.}",

year = "2017",

month = feb,

doi = "10.1002/cpt.455",

language = "English",

volume = "101",

pages = "254--263",

journal = "Clinical Pharmacology & Therapeutics",

issn = "0009-9236",

publisher = "Wiley",

number = "2",

}

Jordan, J, Stinkens, R, Jax, T, Engeli, S, Blaak, EE, May, M, Havekes, B, Schindler, C, Albrecht, D, Pal, P, Heise, T, Goossens, GH & Langenickel, TH 2017, 'Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension', Clinical Pharmacology & Therapeutics, vol. 101, no. 2, pp. 254-263. https://doi.org/10.1002/cpt.455

Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension. / Jordan, J.; Stinkens, R.; Jax, T.; Engeli, S.; Blaak, E. E.; May, M.; Havekes, B.; Schindler, C.; Albrecht, D.; Pal, P.; Heise, T.; Goossens, G. H.; Langenickel, T. H.

In: Clinical Pharmacology & Therapeutics, Vol. 101, No. 2, 02.2017, p. 254-263.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension

AU - Jordan, J.

AU - Stinkens, R.

AU - Jax, T.

AU - Engeli, S.

AU - Blaak, E. E.

AU - May, M.

AU - Havekes, B.

AU - Schindler, C.

AU - Albrecht, D.

AU - Pal, P.

AU - Heise, T.

AU - Goossens, G. H.

AU - Langenickel, T. H.

PY - 2017/2

Y1 - 2017/2

KW - HEART-FAILURE

KW - LIPOLYSIS

KW - LCZ696

KW - METABOLISM

KW - EFFICACY

KW - ADIPOSE

KW - HUMANS

KW - SYSTEM

KW - RISK

KW - MEN

U2 - 10.1002/cpt.455

DO - 10.1002/cpt.455

M3 - Article

VL - 101

SP - 254

EP - 263

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

SN - 0009-9236

IS - 2

ER -